Silexion Therapeutics Corp (NASDAQ:SLXN)’s traded shares stood at 0.31 million during the last session, with the company’s beta value hitting 0.06. At the close of trading, the stock’s price was $1.14, to imply an increase of 2.70% or $0.03 in intraday trading. The SLXN share’s 52-week high remains $122.02, putting it -10603.51% down since that peak but still an impressive 50.0% since price per share fell to its 52-week low of $0.57. The company has a valuation of $9.59M, with an average of 1.37 million shares in intraday trading volume over the past 10 days and average of 14.52 million shares over the past 3 months.
Silexion Therapeutics Corp (NASDAQ:SLXN) trade information
After registering a 2.70% upside in the last session, Silexion Therapeutics Corp (SLXN) has traded red over the past five days. The 5-day price performance for the stock is -12.98%, and 28.09% over 30 days. With these gigs, the year-to-date price performance is -43.28%. Short interest in Silexion Therapeutics Corp (NASDAQ:SLXN) saw shorts transact 0.98 million shares and set a 0.03 days time to cover.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -286.10% for the past 5-year period. While 2025 is set for a 96.36% return in earnings, projections for the next 5 years are at 59.98% annually.
SLXN Dividends
Silexion Therapeutics Corp has its next earnings report out on 2025-Mar-17. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Silexion Therapeutics Corp (NASDAQ:SLXN)’s Major holders
Silexion Therapeutics Corp insiders hold 6.29% of total outstanding shares, with institutional holders owning 7.03% of the shares at 7.50% float percentage. In total, 7.03% institutions holds shares in the company.
Going by data provided on Oct 31, 2024 , Fidelity NASDAQ Composite Index Fund holds roughly 587.0 shares. This is just over 0.03% of the total shares, with a market valuation of $669.0
